Csl Limited · ASX:CSL
Csl — FY2001 Earnings Presentation
11 slides from Csl's earnings presentation, August 2001
Slide 1: Highlights 2000/01
CSL Limited AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY Highlights 2000/01 • Strong Financial Performance – Revenues increase to $855m (70%) – EBITDA increase to $208m (88%) – NPAT(before Amort) to $102m (88%) – NPAT increase to $78.2m (44%) – R&D investment increase to $81.2m (86%) – International sales
Slide 2: Sales by Business Unit and Total Revenues
Sales by Business Unit 2000/01 $843.3m Animal Health 7% Biosciences 13% Bioplasma Pharmaceutical 58% 22% AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY Total Revenues 855 $900 $800 $700 $600 504 425 Million $500 367 $400 $300 $200 $100 $0 1998 1999 2000 2001 Year ending 30 June AUSTRALIA’S BIO-PHARMACEUTICA
Slide 3: Operating Profit after Tax and EBITDA
Operating Profit after Tax 78.2 $80 $70 54.4 $60 47.4 $50 40.9 Million $40 $30 $20 $10 $0 1998 1999 2000 2001 Year ending 30 June AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY EBITDA $250 208 $200 $150 102.4 110.7 Million 90.1 $100 $50 $0 1998 1999 2000 2001 Year ending 30 June AUSTRALIA’S BIO-PHARMACEUTIC
Slide 4: R&D Investment
R&D Investment $90 81.2 $80 $70 $60 40.8 43.6 39.1 Million $50 $40 $30 $20 $10 $0 1998 1999 2000 2001 Year ending 30 June AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY Business Unit Performance AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY 4
Slide 5: Business Unit Performance and Nabi Acquisition
Business Unit Performance • ZLB Bioplasma – strong US sales AUD $133m – IVIG product development – Product demand profile • IVIG • Albumin AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY Nabi Acquisition • Consideration US$152m (A$292m) • 47 Plasma collection centres in 22 US states – 1.3ML of plasma collect
Slide 6: Nabi Acquisition and Extraction Value - Plasma
Nabi Acquisition • Secure plasma supply – Drives increased volumes and earnings from ZLB • Ensures long-term, reliable supply of source plasma – Consolidating source plasma market • Opportunity to increase sales in US and selected key markets Extraction Value - Plasma • Volume/yield growth • Improve
Slide 7: Business Unit Performance
Business Unit Performance • Bioplasma (Australasia) – sales constant – self sufficiency endorsed – donor deferral • Pharmaceutical – sales growth 6% – low yielding influenza strain AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY Business Unit Performance • Animal Health – record sales providing an increase 3
Slide 8: Protein Therapeutic Technologies
Protein Therapeutic Technologies • Plasma fractionation innovation • ISCOM® adjuvant R TB TB R • Recombinant antigens & antibodies AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY Novel Protein Products in the Clinic • HPV -- Merck • Plasma products – rHDL for acute coronary syndromes – (Fibrin Bandage) • ISC
Slide 9: Current Initiatives and Financial Strength
Current Initiatives • Plasma segregation • ZLB capacity expansion • US market commitment • Nabi integration • Influenza capacity expansion AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY Financial Strength • Strong cash flows • Conservative gearing • Quality margins in quality markets • Strong Balance Sheet
Slide 10: Shareholder Value and Group Results 2000/01
Shareholder Value • Key financial focus remains creation of shareholder value • Growth and international market access • Innovation • Leverage technological advantage AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY Group Results 2000/01 2001 2000 $m $m Sales 843.3 450.6 O ther R evenue 11.5 53.7 Total R even
Slide 11: R&D Investment 2000/01 $81.2m
R&D Investment 2000/01 $81.2m Animal Health 9% Biosciences Bioplasma 5% 54% Pharmaceutical 32% AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY 11